OZEMPIC (semaglutide), Novo Nordisk
Indications: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dosage: Subcutaneous injection. Start at 0.25 mg once weekly. After 4 weeks, increase the dose to 0.5 mg once weekly. If after at least 4 weeks additional glycemic control is needed, increase to 1 mg once weekly.
Contraindications: Personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2. Known hypersensitivity to OZEMPIC or any of the product components.